EUROGIN 2026 - List of Posters

LIST OF POSTERS

P03 • EPIDEMIOLOGY AND NATURAL HISTORY

P03-1 • HPV prevalence among Inuit women in Northern Quebec, Canada: A pre- and post-vaccination analysis

P03-2 • Prevalence of human papillomavirus infection by anatomical sites of the urinary tract among the cases with radical cystectomy for bladder cancer

P03-3 • Epidemiological study of patients undergoing high-frequency cervical surgeries at a University Hospital in Brazil, aged 30 to 60 years

P03-4 • Prevalence of HPV genotypes in Brazilian women with cervical cancer and cervical intraepithelial neoplasia: A systematic review and meta-analysis

P03-5 • Long-term risk of gynecologic cancers following HPV testing with Hybrid Capture 2 among women unscreened for over six years: A nationwide cohort study in Taiwan

P03-6 • Long-term hormonal contraceptive use and risk of high-grade cervical lesions in women with high-risk human papillomavirus: A retrospective cohort analysis

P04 • PATHOGENESIS

P04-1 • Hypervirulence through the identification of the genes blaCTX-M-15 and blaNDM in ESBL-producing Klebsiella pneumoniae isolates at the institute of infectious diseases "Professeur Daniel Gahouma" in Libreville

P05 • IMMUNOLOGY

P05-1 • Spatial immune architecture predicts treatment outcomes in HPV-positive oropharyngeal cancer

Brassard P. (Canada)

Fukukawa K. (Japan)

Silveira F. (Brazil)

Santos F. R. (Brazil)

P. T. (Taiwan)

Farzaneh F. (Iran)

Lendoye E. (Gabon)

Wurzba S. (Canada)

P06 • HPV PROPHYLACTIC VACCINES

P06-1 • The identification of HPV prevention strategies between oral health and primary care settings in the United States

P06-2 • Impact of HPV vaccination on the distribution of HPV genotypes in women attending a University Hospital in Buenos Aires, Argentina

P06-3 • It’s not too late to get vaccinated against HPV - The benefits of vaccinating HPVpositive population and patients with cervical intraepithelial neoplasia

P06-4 • Safety and immunogenicity of concomitant first dose of 2-dose regimens of 9-valent HPV and mRNA-1273 vaccines in children aged 9-11 years

P06-5 • Final results of a 5-year immunogenicity and safety study of the 9-valent human papillomavirus vaccine in Chinese females aged 9-45 years

Richman A. (USA)

Fleider L. (Argentina)

Pruski D. (Poland)

Luxembourg A. (USA)

P08 • IMMUNOTHERAPY - IMMUNO-ONCOLOGY - NEW TREATMENTS

P08-1 • Legal aspects of underestimation and overestimation of diagnosis and treatment of precancerous conditions and cervical cancer

P09 • HPV TESTING

P09-1 • Epidemiology, genotypic diversity and age-specific risk pattern of circulating human papillomavirus in Dhaka City, Bangladesh: A five-year study (2020-2024)

P09-2 • Prevalence of high-risk HPV genotypes and their correlation with cervical cytology in Georgian women

P09-3 • Prevalence of different types of human papilloma virus infection in anal samples and impact of co-testing: Findings from a public university Greek hospital

P09-4 • Prevalence of different types of vaginal human papilloma virus infection and impact of co-testing: Findings from a public university Greek hospital

P09-5 • Ten-year results of HPV and cytological testing from the National Reference Centre, Zagreb, Croatia

P09-6 • Impact of low HPV vaccination coverage on infection rates and cytological findings in women in Bulgaria

P09-7 • HPV biomarkers in oral derived body fluids in oropharyngeal cancer patients

P09-8 • Novel HPV reference materials representing normalized viral load for use in assay validation

P09-9 • Analytical agreement between the SD biosensor STANDARD M10 hr-HPV assay and the RIATOL qPCR genotyping test applied to channel-specific hrHPV detection

Ochocka W. (Poland)

Morshed R. A. (Bangladesh)

Pantsulaia A. (Georgia)

Sopaki Valalaki A. (Greece)

Pantazi E. (Greece)

Marijan T. (Croatia)

Petkova E. (Bulgaria)

Doni M. (Italy)

Zhelev P. (Canada)

Laermans Z. (Belgium)

Torres M. M. (Colombia) P10 • HPV SCREENING

P10-1 • Patient acceptability of CITOBOT for cervical cancer screening: A mixedmethod study

P11 • SCREENING FOR WOMEN DIFFICULT TO REACH

P11-1 • Self-sampling for cervical screening in the transgender and non-binary community: A qualitative study

P11-2 • Acceptability of urine self-collection for (human papillomavirus) HPV testing among U.S. low-income women

P11-3 • Urine HPV testing for cervical cancer screening among Malaysian womenFeasibility and accuracy

P11-4 • Structured implementation of cervical cancer screening & dysplasia treatment in Ghana: Implementing sustainable care in a low-resource setting

P11-5 • Participation after implementation of self-sampling in cervical cancer screening among Long-Term Non-Attenders (LTNAs) with severe mental illness in Stockholm

P12 • TRIAGE OF HPV POSITIVE WOMEN

P12-1 • Between molecules and microscopes: Lessons from Romanian cervical screening in the age of precision diagnostics

P12-2 • The impact of bisulfite conversion method on FAM19A4/miR124-2 methylation testing in cervical samples with low-DNA input

P13 • SELF-SAMPLING

P13-1 • Large-scale paired comparative study on women’s preference of self-collection devices and their opinion on self-sampling for cervical cancer screening

P13-2 • Impact of home-based cervical cancer screening on other preventive health service utilization: An analysis of flu vaccine uptake

P13-3 • Analytical and diagnostic quality of biobanked HPV Self-samples for cervical cancer screening after storage

P13-4 • Streamlining HPV screening: UniVerse ® automated workflow for self-collected vaginal swabs

Davies-Oliveira J. (UK)

E. (USA)

R. (Malaysia)

Pan T. L. (Austria)

Abdullayev K. (UK)

Mitran M. (Romania)

Tavčar Kunstič T. (Slovenia)

Korsgaard Andreasen E. (Denmark)

Molino A. (USA)

Arum A. (Denmark)

Di Costanzo S. (Italy)

P13 • SELF-SAMPLING

P13-5 • Self-sampling HPV screening with DH3, a hybrid capture-based HPV test with HPV16/18 genotyping

P13-6 • Cloud-based cervical cancer screening with high follow-up rates: A scalable self-sampling approach in Cambodia

P13-7 • Incidence of cervical cancer in Sweden after switching to HPV-based selfsampling in general screening

P13-8 • Maintaining continuity of community HPV self-sampling and result tacking in disrupted operating environments

P13-9 • Veil-based self-collected cervicovaginal sampling for site-of-care sexually transmitted infections and primary HPV-based cervical cancer screening: A largescale pilot feasibility study in Romania

P14 • GENOTYPING

P14-1 • Detection and genotyping of human papillomavirus (HPV) in liquid-based cytology samples from a rural region of São Paulo state (Vale do Ribeira), Brazil

Hua B. (China)

Caixeta Borges I. (Germany)

Andersson H. (Sweden)

Angaw D. A. (Ethiopia)

Bélec L. (France)

P14-2 • Optimizing cervical cancer screening: The value of HPV testing in West Algeria

P14-3 • Analysis of high-risk HPV infection trends in women triaged with Anyplex II HPV HR assay and SG STATS platform

P14-4 • High-risk human papillomavirus (HPV) genotype-specific distribution in HPVpositive women from Southern Croatia, using full genotyping

P15 • MOLECULAR MARKERS

P15-1 • Circulating plasma miRNA signature associated with HPV-related high-grade cervical intraepithelial neoplasia

P15-2 • Discordant phenotypes in penile squamous cell carcinoma

P15-3 • Association of iron metabolism genetic variants in HFE and TMPRSS6 genes and HPV infection in lung cancer risk

P15-4 • Expression profiles of selected microRNAs as potential biomarkers in cervical lesion progression

P15-5 • Evaluation of Torque Teno Virus (TTV) as a potential biomarker of immune status in relation to high-risk HPV infection in cervical samples

Lorente S. (Brazil)

Masdoua N. (Algeria)

Miceska S. (Slovenia)

Kaliterna V. (Croatia)

Calfa S. (Brazil)

Koller M. (Austria)

Bicho M. C. (Portugal)

Hornakova A. (Slovakia)

Hantz S. (France)

P16 • SCREENING METHODS

P16-1

• The evaluation of filter paper as a urine specimen collection method for HPV detection and genotyping

P16-2 • Correlation between HPV testing and histological findings in adult women in Pleven

P16-3 • In the era of co-testing, can the LuViva test qualify patients for colposcopy?

- A pilot study

P16-4 • Vulvovaginitis molecular diagnosis: Study of potential etiological agents in a Portuguese cohort

P17 • METHYLATION

P17-1 • DNA-methylation markers for early endometrial cancer detection in patient-collected urine and vaginal samples - A case control study

P17-2 • Our brief experience with methylation

P17-3 • Methylation status of cell adhesion molecules in early detection of cervical cancer

P18 • MICROBIOME

P18-1 • Comparative analysis of HPV genotyping and microbiome profile in uterine cervix samples obtained by urine, self-collection, and healthcare professionals

P18-2 • Aerobic vaginitis diagnosis criteria combining gram stain with molecular panel RT-qPCR: A improve aprroach

P18-3 • Interactions between human papillomavirus infection and vaginal microbiota imbalance: The role of bacterial vaginosis in cervical dysplasia

P18-4 • Cervico-vaginal dysbiosis and FAM19A4/miR-124-2 methylation in cervical intraepithelial neoplasia

P18-5 • Anal microbiome in MSM living with HIV: Correlation with HPV16 infection and high-grade squamous intraepithelial lesions

P18-6 • Longitudinal assessment of vaginal microbiome composition and HPV clearance among women in Nairobi, Kenya

P18-7• Characteristics of vaginal microbiota in high-grade squamous intraepithelial lesions of the uterine cervix for patients following eubiosis maintenance protocol

Schulz V. (Canada)

Hinkova N. (Bulgaria)

Millert-Kalińska S. (Poland)

Costa M. (Portugal)

Binderup K. O. (Denmark)

Grigoriu C. (Romania)

Holubekova V. (Slovakia)

Dahrouge-Chiarot F. (Brazil)

Ramos de Leu Sampaio P. (Brazil)

Gincheva D. (Bulgaria)

Socolov D. G. (Romania)

Donà M. G. (Italy)

Shakery T. (Canada)

Borba Souza K. C. (Brazil)

P20 • NEW TECHNOLOGIES

P20-1

• New biomarker E7 oncoprotein detected using self-sampling and self-testing E7 oncoprotein rapid test assay for cervical cancer screening

P20-2 • Bridging and diagnostic evaluation of the HPV PLUS ELITe MGB® kit from the ELITe InGenius to ELITe BeGenius sample to result PCR system

P22 • DIAGNOSTIC PROCEDURES / MANAGEMENT

P22-1 • The additive value of routine endocervical curettage at loop conization for future management of cervical dysplasia

P22-2 • HPV RNA and DNA analysis as potential diagnostic tool for nodal metastasis in cervical cancer

P22-3 • Application of vaginal gel with Coriolus versicolor after operative treatment of cervical intraepithelial neoplasia – Case series

P23 • RISK MANAGEMENT

P23-1 • Heterogeneity of CIN2 diagnosis and risk of progression: A Danish historical cohort study

P23-2 • Risk factors associated with disease recurrence following cervical conization

P23-3 • HPV test clearance after LEEP in women with high-grade squamous intraepithelial lesions and its association with persistence and recurrence

P25 • CERVICAL NEOPLASIA

Miao J. (USA)

S. (Italy)

Ochshorn Y. (Israel)

Le S. P. A. (Germany)

Trajkovikj S. (North Macedonia)

Tarpoe C. (Denmark)

Zsombor Rezső H. (Hungary)

Godoi Lopes L. (Brazil)

P25-1 • Clinical value of HPV genotyping in women with biopsy-negative or low-grade cervical intraepithelial neoplasia

P25-2 • Retrospective analysis of the effectiveness of laser vaporization for cervical lesions

P25-3 • Effectiveness of a coriolus versicolor-based vaginal gel on cervical reepithelialization, bleeding and hr-HPV clearance after excisional treatment: Preliminary results

P25-4 • Efficacy of a multi-ingredient coriolus versicolor-based vaginal gel in hr-HPV clearance: Final pooled results from the PALOMA 1 and PALOMA 2 clinical trials

P25-5 • Early up-regulation of ROMO1 in cervical intraepithelial neoplasia: Evidence of HPV-driven oxidative stress in precancerous lesions

Ju U. (South Korea)

Jan č ar N. (Slovenia)

Álvarez C. (Spain)

Serrano L. (Spain)

Tsoneva E. (Bulgaria)

P27 • ANAL NEOPLASIA

P27-1 • Concordance and acceptability of self- VS clinician-collected anorectal swabs for HPV genotyping in gay, bisexual and other men who have sex with men

P28 • ORAL HPV INFECTION

P28-1 • Oral and genital high-risk HPV infection in a young male with oral lichen planus: Case report

P29 • HPV AND OROPHARYNX / HEAD AND NECK CANCER

P29-1• Socio-demographic characteristics of People with HPV-associated oropharyngeal cancer in Iowa, US

P29-2 • Fibroblast supernatants modulate treatment responses in human papillomavirus positive and negative oropharyngeal cancer cell lines

P29-3 • Early detection of minimal residual disease using circulating tumour HPV-DNA in HPV-associated head and neck squamous cell carcinoma

P29-4 • HPV-associated oropharyngeal carcinomas - A Romanian institutional study

P29-5 • Molecular and immunohistochemical annotation of HPV in oropharyngeal cancer: Extent and clinical implications of discordance

P29-6 • Prevalence and genotypic distribution of human papillomavirus (HPV) in the oral cavity of transgender women in women in Central Brazil

P32 • HPV TRANSMISSION

Paytubi S. (Spain)

Petrovic A. (Serbia)

Askelson N. (USA)

Kostopoulou O. N. (Sweden)

Oldaeus Almerén A. (Sweden)

Mitran L. (Romania)

Connor L. (UK)

Carneiro M. (Brazil)

P32-1 • Is there a good statistical correlation between biopsy results and conization outcomes at our center?

P34 • CONVENTIONAL THERAPIES

P34-1 • Medical therapy of genital human papilloma virus-related disease - Case series and treatment approach

P34-2 • The current application status of photodynamic therapy for cervical HSIL in China

P34-3 • Breaking down the barrier: Enzymatic strategy to overcome biofilm-mediated resistance in urogenital infections

Yera Gilabert M. (Spain)

Talevska Trajanovikj B. (North Macedonia)

Wei L. (China)

Dubrovina S. (Russia)

P35 • ECONOMICS AND MODELLING

P35-1 • Cost-effectiveness analysis of catch-up HPV-vaccinations in Austria Boschek F. (Sweden)

P36 • ADVOCACY, ACCEPTABILITY AND PSYCHOLOGY

P36-1 • Improved quality of life and emotional well-being after diathermy ablation for cervical intraepithelial neoplasia: A prospective study

P36-2 • Cervical cancer: Main determinants of delayed diagnosis and ways to eliminate them

P37 • HEALTH

EDUCATION

Fujii T. (Japan)

Mamadieva G. (Uzbekistan)

P37-1 • Enhancing HPV vaccine acceptance in school-based programs: Assessment of the immune patrol game in Quebec, Canada

P37-2 • Assessing the impact of HPV 9 in 9: A high-production educational video to enhance pharmacist confidence and uptake in HPV vaccination

P39 • PUBLIC HEALTH

P39-1 • Health equity and human papillomavirus interventions for adolescents: A systematic review

P39-2 • Acceptance and attitudes towards risk-based cancer screening among general population women: A mixed methods systematic review

P39-3 • Cervical cancer elimination in Manitoba: An exploration of the current state and opportunities for successful elimination in the future

P39-4 • Every opportunity counts: Rural-Urban differences in public comfort of dental settings for HPV-related discussions in the United States

P39-5 • “Those who tested positive should be the ones sensitizing others”: Socio-ecological factors of loss to follow-up among HPVpositive women in a door-to-door HPV self-sampling screening program in Cameroon

P39-6 • Microbiological profile of symptomatic vaginal discharge at the Institute of Infectious Diseases Professor Daniel Gahouma In Libreville, Gabon

P39-7 • HPV genotypes in women diagnosed with HSIL+ in Northeastern Brazil: Evaluating the protective impact of the HPV vaccine

Sauvageau C. (Canada)

Zhou M. (Canada)

Maness S. (USA)

Remmel M. L. (Estonia)

O'Conaill C. (Canada)

Merrell L. (USA)

Datchoua Moukam A. M. (Switzerland)

Chansi Kengni Ankely H. J. (Gabon)

Eleutério Junior J. (Brazil)

P39 • PUBLIC HEALTH

P39-8 • Effectiveness of trainings for healthcare professionals to human papillomavirus (HPV) vaccination

P39-9 • Impact of HPV vaccination on cervical preneoplastic lesions in Colombia: Analysis of national health databases

P39-10 • Empowering communities for cervical cancer elimination: A contextual prevention model from rural Namibia

Gerlich M. (Germany)